Literature DB >> 18624729

Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells.

Ivana Stojanović1, Tamara Cvjetićanin, Sandra Lazaroski, Stanislava Stosić-Grujicić, Djordje Miljković.   

Abstract

Interleukin (IL)-17 is a pro-inflammatory cytokine produced by recently described T helper type 17 (Th17) cells, which have critical role in immunity to extracellular bacteria and the pathogenesis of several autoimmune disorders. IL-6 and transforming growth factor (TGF)-beta are crucial for the generation of Th17 cells in mice, while the production of IL-17 is supported by various cytokines, including IL-23, IL-1beta, IL-21, IL-15 and tumour necrosis factor (TNF)-alpha. In this study, the influence of a multifunctional cytokine, macrophage migration inhibitory factor (MIF), on IL-17 production in mice was investigated. Treatment of lymph node cells (LNCs) with recombinant MIF up-regulated mitogen-stimulated IL-17 expression and secretion. Additionally, LNCs from MIF knockout mice (mif(-/-)) had severely impaired production of IL-17, as well as of IL-1beta, IL-6, IL-23 and TGF-beta. When stimulated with recombinant IL-1beta, IL-23 or TNF-alpha, mitogen-triggered mif(-/-) LNCs were fully able to achieve the IL-17 production seen in wild-type (WT) LNCs, while the addition of IL-6 and TGF-beta had no effect. Finally, after injection of mice with complete Freund's adjuvant, secretion of IL-17 as well as the number of IL-17-positive cells was significantly lower in the draining lymph nodes of mif(-/-) mice in comparison with WT mice. The effect of MIF on IL-17 production was dependent on p38, extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK) and Janus kinase 2/signal transducer and activator of transcription 3 (Jak2/STAT3), and not on nuclear factor (NF)-kappaB and nuclear factor of activated T cells (NFAT) signalling. Bearing in mind the contribution of MIF and IL-17 to the pathology of inflammatory and autoimmune disorders, from the results presented here it seems plausible that targeting MIF biological activity could be a valid therapeutic approach for the treatment of such diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18624729      PMCID: PMC2632697          DOI: 10.1111/j.1365-2567.2008.02879.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  38 in total

1.  Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.

Authors:  Sudeepta Aggarwal; Nico Ghilardi; Ming-Hong Xie; Frederic J de Sauvage; Austin L Gurney
Journal:  J Biol Chem       Date:  2002-11-03       Impact factor: 5.157

2.  MIF regulates innate immune responses through modulation of Toll-like receptor 4.

Authors:  T Roger; J David; M P Glauser; T Calandra
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

Review 3.  Macrophage migration inhibitory factor.

Authors:  John A Baugh; Richard Bucala
Journal:  Crit Care Med       Date:  2002-01       Impact factor: 7.598

4.  Up-regulation of human beta-defensin 2 by interleukin-1beta in A549 cells: involvement of PI3K, PKC, p38 MAPK, JNK, and NF-kappaB.

Authors:  Byeong-Churl Jang; Ki-Jo Lim; Ji-Hye Paik; Young-Kyu Kwon; Sang-Woo Shin; Sang-Chan Kim; Tae-Young Jung; Taeg Kyu Kwon; Jae-We Cho; Won-Ki Baek; Sang-Pyo Kim; Min-Ho Suh; Seong-Il Suh
Journal:  Biochem Biophys Res Commun       Date:  2004-07-30       Impact factor: 3.575

5.  Blockade of macrophage migration inhibitory factor ameliorates experimental autoimmune myocarditis.

Authors:  Yutaka Matsui; Hiroshi Okamoto; Nan Jia; Masatoshi Akino; Toshimitsu Uede; Akira Kitabatake; Jun Nishihira
Journal:  J Mol Cell Cardiol       Date:  2004-08       Impact factor: 5.000

6.  IL-10 inhibits the synthesis of migration inhibitory factor and migration inhibitory factor-mediated macrophage activation.

Authors:  J Wu; F Q Cunha; F Y Liew; W Y Weiser
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

7.  Taxol activates inducible nitric oxide synthase in rat astrocytes: the role of MAP kinases and NF-kappaB.

Authors:  I Cvetkovic; D Miljkovic; O Vuckovic; L Harhaji; Z Nikolic; V Trajkovic; M Mostarica Stojkovic
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

8.  MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia.

Authors:  J Bernhagen; T Calandra; R A Mitchell; S B Martin; K J Tracey; W Voelter; K R Manogue; A Cerami; R Bucala
Journal:  Nature       Date:  1993-10-21       Impact factor: 49.962

9.  Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy.

Authors:  Joseph C K Leung; Loretta Y Y Chan; Anita W L Tsang; Emily W L Liu; Man Fai Lam; Sydney C W Tang; Kar Neng Lai
Journal:  Nephrol Dial Transplant       Date:  2004-06-08       Impact factor: 5.992

Review 10.  Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential.

Authors:  Marie A Bogoyevitch; Ingrid Boehm; Aaron Oakley; Albert J Ketterman; Renae K Barr
Journal:  Biochim Biophys Acta       Date:  2004-03-11
View more
  24 in total

Review 1.  Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection.

Authors:  I Mirkov; S Stosic-Grujicic; M Kataranovski
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 2.  Beta cell function: the role of macrophage migration inhibitory factor.

Authors:  Ivana Stojanovic; Tamara Saksida; Stanislava Stosic-Grujicic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential.

Authors:  Joshua Bloom; Christine Metz; Saisha Nalawade; Julian Casabar; Kai Fan Cheng; Mingzhu He; Barbara Sherry; Thomas Coleman; Thomas Forsthuber; Yousef Al-Abed
Journal:  J Biol Chem       Date:  2016-10-28       Impact factor: 5.157

Review 4.  Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis.

Authors:  Suling Liu; Yang Cui; Xiao Zhang
Journal:  Clin Rheumatol       Date:  2020-06-06       Impact factor: 2.980

Review 5.  Interleukin-23: as a drug target for autoimmune inflammatory diseases.

Authors:  Chunlei Tang; Shu Chen; Hai Qian; Wenlong Huang
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

6.  Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice.

Authors:  Guoliang Cui; Xia Qin; Yuebo Zhang; Zhenwei Gong; Baoxue Ge; Ying Qin Zang
Journal:  J Biol Chem       Date:  2009-08-06       Impact factor: 5.157

7.  Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients.

Authors:  Jiang Li; Hao-Yuan Mo; Geng Xiong; Lin Zhang; Jia He; Zhou-Feng Huang; Zhi-Wei Liu; Qiu-Yan Chen; Zi-Ming Du; Li-Min Zheng; Chao-Nan Qian; Yi-Xin Zeng
Journal:  J Biol Chem       Date:  2012-08-14       Impact factor: 5.157

Review 8.  Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Joshua B Bilsborrow; Edward Doherty; Pathricia V Tilstam; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2019-08-20       Impact factor: 6.902

9.  Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model.

Authors:  C Escudero-Lourdes; M K Medeiros; M C Cárdenas-González; S M Wnek; J A Gandolfi
Journal:  Toxicol Appl Pharmacol       Date:  2010-01-04       Impact factor: 4.219

10.  Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables.

Authors:  L A Bautista-Herrera; U De la Cruz-Mosso; R Morales-Zambrano; G D Villanueva-Quintero; J Hernández-Bello; M G Ramírez-Dueñas; E Martínez-López; L M Brennan-Bourdon; C J Baños-Hernández; J F Muñoz-Valle
Journal:  Clin Exp Med       Date:  2017-09-30       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.